Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon Phase 3 Study for CKD-associated Pruritus
NCT05135390Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing HSK21542 with Placebo (2 arms). Primary endpoint: Proportion of subjects with an improvement of >= 4 points in Worst Itch Numeric Rating Scale at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
hsk21542
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05135390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135390.